Off-the-Shelf immune cell therapy tested in Tough-to-Treat lymphoma
NCT ID NCT06285422
Summary
This is a first-in-human study to test the safety of a new type of 'off-the-shelf' immune cell therapy called SC262. It is for adults with non-Hodgkin's lymphoma whose cancer has come back or stopped responding to treatment, including a prior CAR-T therapy. The main goal is to find a safe dose and see how the body handles the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The University of Kansas Hospital
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.